|
#61
19.12.2008, 20:57
|
||||
|
||||
|
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 
|
|
#62
24.12.2008, 11:59
|
||||
|
||||
|
Ãèëÿðîâó Ì.Þ. è æåëàþùèì
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study)
|
|
#63
11.01.2009, 13:23
|
|||
|
|||
|
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness
Criteria for Coronary Revascularization [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#64
11.01.2009, 20:16
|
|||
|
|||
|
Êòî åùå íå îáçàâåëñÿ - ðåêîìåíäóþ, î÷åíü óäîáíî è îáíîâëÿåòñÿ õîðîøî. Óñòàíàâëèâàåòå è âñÿ áàçà ó âàñ â êîìïàêòíîì âèäå.
American Heart Association: Core Collection 2008 CD Core Collection 2008 is a compilation of the American Heart Association’s Scientific Statements and Practice Guidelines. All of the AHA’s definitive scientific content is presented in an easy to use interface that facilitates searching, aggregating, bookmarking, and updating. The content on the CD-ROM is just the beginning. Throughout the year, as new Scientific Statements and Practice Guidelines are released, users with an Internet connection will be alerted to new content available and given the opportunity to update their Core Collection. 220.51 MB rar .exe file [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] èëè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#65
13.01.2009, 10:04
|
||||
|
||||
|
Öèòàòà:
|
|
#66
13.01.2009, 11:23
|
|||
|
|||
|
Êàê ïðàâèëî íàæèìàåòå íà ïåðâóþ ÷àñòü, ïðàâàÿ êëàâèøà - èçâëå÷ü, âûáèðàåòå - ìîæíî èçâëå÷ü çäåñü èëè â îäíîèìåííóþ ïî íàçâàíèþ àðõèâà ïàïêó. Êàê ïðàâèëî îí ñàì íàõîäèò âñå ÷àñòè è ðàñïàêîâûâàåòñÿ. Èíîãäà âîçìîæíî âûäåëèòü âñå 3 ÷àñòè, íà ëþáîé ÷àñòè ïðàâàÿ êëàâèøà èçâëå÷ü è òîæå ñàìîå ïðîèñõîäèò.
|
|
#67
13.01.2009, 21:57
|
|||
|
|||
|
Öèòàòà:
|
|
#68
13.01.2009, 22:01
|
|||
|
|||
|
Óæå ñòàðåíüêàÿ, íî ïî-ïðåæíåìó àêòóàëüíàÿ êíèãà ïî êàðäèîëîãèè.
Hurst's the Heart, 12th Edition (Hurst's the Heart) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Handbook of Cardiac Electrophysiology 2007 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Mayo Clinic Cardiology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Íàâåðíîå, ëó÷øå óáðàòü â æåëòîå.
|
|
#70
14.01.2009, 05:02
|
||||
|
||||
|
Ðàç ïîøëà òàêàÿ ïüÿíêà......
 Thoracic Aortic Diseases // Hervé Rousseau (Editor), Jean-Philippe Verhoye (Editor), Jean-Francois Heautot - PDF, 11.52 MB [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïî-ìîåìó, êëàññíàÿ êíèæêà!
|
|
#73
27.01.2009, 18:56
|
|||
|
|||
|
Ìíå êàæåòñÿ, ÷òî ýòî èíòåðåñíàÿ èíôîðìàöèÿ
Clopidogrel bisulfate (marketed as Plavix)Audience: Cardiovascular healthcare professionals, Pharmacists [Posted 01/26/2009] FDA notified healthcare professionals that the makers of Plavix have agreed to work with FDA to conduct studies to obtain additional information that will allow a better understanding and characterization of the effects of genetic factors and other drugs (especially the proton pump inhibitors (PPIs)) on the effectiveness of clopidogrel. FDA is aware of published reports that clopidogrel (marketed as Plavix) is less effective in some patients than it is in others. Differences in effectiveness may be due to genetic differences in the way the body metabolizes clopidogrel or that using certain other drugs with clopidogrel can interfere with how the body metabolizes clopidogrel. These studies should lead to a better understanding about how to optimize the use of clopidogrel. The FDA recognizes the importance of obtaining these data promptly. The drug manufacturers have agreed to a timeline for completing the studies and FDA will review the new information expeditiously and will communicate its conclusions and any recommendations to the public at that time. It could take several months to complete the studies and analyze the results. Until further information is available FDA recommends the following: · Healthcare providers should continue to prescribe and patients should continue to take clopidogrel as directed, because clopidogrel has demonstrated benefits in preventing blood clots that could lead to a heart attack or stroke. · Healthcare providers should re-evaluate the need for starting or continuing treatment with a PPI, including Prilosec OTC, in patients taking clopidogrel. · Patients taking clopidogrel should consult with their healthcare provider if they are currently taking or considering taking a PPI, including Prilosec OTC.
|
|
#75
27.01.2009, 22:42
|
|||
|
|||
|
Öèòàòà:
Çäåñü ïðåäñòàâëåíà òîëüêî âåðõóøêà àéñáåðãà.
|
Ëèíåéíûé âèä
